Ikeda H, et al. - With clinical trials demonstrating high effectiveness and safety, glecaprevir/pibrentasvir (G/P) treatment has been recommended for 8 weeks for hepatitis C virus (HCV) infected patients who are direct-acting antiviral naïve, genotype 1 or 2, and non-cirrhotic, so researchers assessed the real-world experience with 8-week G/P treatment in Japan. This prospective observational cohort study included 554 patients who underwent 8-week treatment from among 1,022 patients who initiated G/P therapy. With a sustained virological response rate of 92.8% (530/571) at 12 weeks in the intention-to-treat population and 99.3% (526/530) in the per protocol population, G/P treatment for 8 weeks was identified as safe and effective for these patients in a real-world clinical setting in Japan.